778 related articles for article (PubMed ID: 11694805)
1. Comparison of the bronchodilating effect of salmeterol and zafirlukast in combination with that of their use as single treatments in asthma and chronic obstructive pulmonary disease.
Cazzola M; Centanni S; Boveri B; Di Marco F; Santus P; Matera MG; Allegra L
Respiration; 2001; 68(5):452-9. PubMed ID: 11694805
[TBL] [Abstract][Full Text] [Related]
2. Comparison of inhaled salmeterol and oral zafirlukast in asthmatic patients using concomitant inhaled corticosteroids.
Nelson HS; Nathan RA; Kalberg C; Yancey SW; Rickard KA
MedGenMed; 2001 Jul; 3(4):3. PubMed ID: 11549982
[TBL] [Abstract][Full Text] [Related]
3. Decreased bronchodilating effect of salbutamol in relieving methacholine induced moderate to severe bronchoconstriction during high dose treatment with long acting beta2 agonists.
van der Woude HJ; Winter TH; Aalbers R
Thorax; 2001 Jul; 56(7):529-35. PubMed ID: 11413351
[TBL] [Abstract][Full Text] [Related]
4. Effects of formoterol, salmeterol or oxitropium bromide on airway responses to salbutamol in COPD.
Cazzola M; Di Perna F; Noschese P; Vinciguerra A; Calderaro F; Girbino G; Matera MG
Eur Respir J; 1998 Jun; 11(6):1337-41. PubMed ID: 9657576
[TBL] [Abstract][Full Text] [Related]
5. Comparison of inhaled salmeterol and oral zafirlukast in patients with asthma.
Busse W; Nelson H; Wolfe J; Kalberg C; Yancey SW; Rickard KA
J Allergy Clin Immunol; 1999 Jun; 103(6):1075-80. PubMed ID: 10359889
[TBL] [Abstract][Full Text] [Related]
6. Inhaled salmeterol: a review of its efficacy in chronic obstructive pulmonary disease.
Jarvis B; Markham A
Drugs Aging; 2001; 18(6):441-72. PubMed ID: 11419918
[TBL] [Abstract][Full Text] [Related]
7. Lung function improvement in smokers suffering from COPD with zafirlukast, a CysLT(1)-receptor antagonist.
Cazzola M; Boveri B; Carlucci P; Santus P; DiMarco F; Centanni S; Allegra L
Pulm Pharmacol Ther; 2000; 13(6):301-5. PubMed ID: 11061985
[TBL] [Abstract][Full Text] [Related]
8. A comparison between inhaled salmeterol and theophylline in the short-term treatment of stable chronic obstructive pulmonary disease.
Broseghini C; Testi R; Polese G; Tosatto R; Rossi A
Pulm Pharmacol Ther; 2005; 18(2):103-8. PubMed ID: 15649852
[TBL] [Abstract][Full Text] [Related]
9. Bronchodilator effect of an inhaled combination therapy with salmeterol + fluticasone and formoterol + budesonide in patients with COPD.
Cazzola M; Santus P; Di Marco F; Boveri B; Castagna F; Carlucci P; Matera MG; Centanni S
Respir Med; 2003 May; 97(5):453-7. PubMed ID: 12735659
[TBL] [Abstract][Full Text] [Related]
10. Nebulized arformoterol in patients with COPD: a 12-week, multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled trial.
Baumgartner RA; Hanania NA; Calhoun WJ; Sahn SA; Sciarappa K; Hanrahan JP
Clin Ther; 2007 Feb; 29(2):261-78. PubMed ID: 17472819
[TBL] [Abstract][Full Text] [Related]
11. Inhaled corticosteroids do not prevent the development of tolerance to the bronchoprotective effect of salmeterol.
Kalra S; Swystun VA; Bhagat R; Cockcroft DW
Chest; 1996 Apr; 109(4):953-6. PubMed ID: 8635376
[TBL] [Abstract][Full Text] [Related]
12. Oral bambuterol compared to inhaled salmeterol in patients with partially reversible chronic obstructive pulmonary disease.
Cazzola M; Calderaro F; Califano C; Di Pema F; Vinciguerra A; Donner CF; Matera MG
Eur J Clin Pharmacol; 1999 Jan; 54(11):829-33. PubMed ID: 10027655
[TBL] [Abstract][Full Text] [Related]
13. Comparable spirometric efficacy of tiotropium compared with salmeterol plus fluticasone in patients with COPD: a pilot study.
Bateman ED; van Dyk M; Sagriotis A
Pulm Pharmacol Ther; 2008; 21(1):20-5. PubMed ID: 17118684
[TBL] [Abstract][Full Text] [Related]
14. Salmeterol xinafoate as maintenance therapy compared with albuterol in patients with asthma.
D'Alonzo GE; Nathan RA; Henochowicz S; Morris RJ; Ratner P; Rennard SI
JAMA; 1994 May; 271(18):1412-6. PubMed ID: 7909853
[TBL] [Abstract][Full Text] [Related]
15. Early reversibility to salbutamol does not always predict bronchodilation after salmeterol in stable chronic obstructive pulmonary disease.
Cazzola M; Vinciguerra A; Di Perna F; Matera MG
Respir Med; 1998 Aug; 92(8):1012-6. PubMed ID: 9893768
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of inhaled salmeterol in the management of smokers with chronic obstructive pulmonary disease: a single centre randomised, double blind, placebo controlled, crossover study.
Ulrik CS
Thorax; 1995 Jul; 50(7):750-4. PubMed ID: 7570409
[TBL] [Abstract][Full Text] [Related]
17. Effects of adding a leukotriene antagonist or a long-acting beta(2)-agonist in asthmatic patients with the glycine-16 beta(2)-adrenoceptor genotype.
Lipworth BJ; Dempsey OJ; Aziz I; Wilson AM
Am J Med; 2000 Aug; 109(2):114-21. PubMed ID: 10967152
[TBL] [Abstract][Full Text] [Related]
18. Acute effects of higher than customary doses of salmeterol and salbutamol in patients with acute exacerbation of COPD.
Cazzola M; Califano C; Di Perna F; D'Amato M; Terzano C; Matera MG; D'Amato G; Marsico SA
Respir Med; 2002 Oct; 96(10):790-5. PubMed ID: 12412978
[TBL] [Abstract][Full Text] [Related]
19. Inhaled salmeterol and fluticasone: a study comparing monotherapy and combination therapy in asthma.
Pearlman DS; Stricker W; Weinstein S; Gross G; Chervinsky P; Woodring A; Prillaman B; Shah T
Ann Allergy Asthma Immunol; 1999 Mar; 82(3):257-65. PubMed ID: 10094216
[TBL] [Abstract][Full Text] [Related]
20. Zafirlukast: an update of its pharmacology and therapeutic efficacy in asthma.
Dunn CJ; Goa KL
Drugs; 2001; 61(2):285-315. PubMed ID: 11270943
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
